Potential of serum soluble CD93 as a biomarker for asthma in an ovalbumin-induced asthma murine model

Hye Jung Park, Eun Yi Oh, Yoon Hee Park, Misuk Yang, Kyung Hee Park, Jungwon Park, Jae Hyun Lee

Research output: Contribution to journalArticle

Abstract

Background: CD93 is a membrane-associated glycoprotein, which can be released in a soluble form (sCD93) into the serum. CD93 has received renewed attention as a candidate biomarker of inflammation in various inflammatory and immune-mediated diseases, including asthma. Objective: We aimed to evaluate the effects of airway inflammation on CD93 levels in murine models. Methods: We established an ovalbumin (OVA)-induced acute asthma murine model (OVA model) and a lipopolysaccharide (LPS)-induced airway inflammation murine model (LPS model). Dexamethasone was administered by gavage to attenuate the airway inflammation. Results: The OVA model demonstrated typical allergic asthma features with increased airway hyper-responsiveness, inflammatory cell infiltration, increased Th2 cytokine levels, compared to the control group. CD93 levels were decreased in lung homogenates and, respiratory epithelial cells, whereas serum sCD93 levels were increased in the OVA model, as compared to the control group. Dexamethasone reversed these effects of OVA. In contrast, in the LPS model, CD93 levels were not affected in neither respiratory epithelial cells nor serum. Conclusions: Our findings demonstrate the potential of using sCD93 as a biomarker for allergic asthma.

Original languageEnglish
Pages (from-to)446-452
Number of pages7
JournalBiomarkers
Volume23
Issue number5
DOIs
Publication statusPublished - 2018 Jul 4

Fingerprint

Ovalbumin
Biomarkers
Asthma
Inflammation
Lipopolysaccharides
Serum
Dexamethasone
Respiratory Hypersensitivity
Epithelial Cells
Control Groups
Immune System Diseases
Membrane Glycoproteins
Cytokines
Lung
Infiltration
Glycoproteins
Membranes

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Cite this

Park, Hye Jung ; Oh, Eun Yi ; Park, Yoon Hee ; Yang, Misuk ; Park, Kyung Hee ; Park, Jungwon ; Lee, Jae Hyun. / Potential of serum soluble CD93 as a biomarker for asthma in an ovalbumin-induced asthma murine model. In: Biomarkers. 2018 ; Vol. 23, No. 5. pp. 446-452.
@article{3ca6769959cf4d5eba310b5a966cf0cc,
title = "Potential of serum soluble CD93 as a biomarker for asthma in an ovalbumin-induced asthma murine model",
abstract = "Background: CD93 is a membrane-associated glycoprotein, which can be released in a soluble form (sCD93) into the serum. CD93 has received renewed attention as a candidate biomarker of inflammation in various inflammatory and immune-mediated diseases, including asthma. Objective: We aimed to evaluate the effects of airway inflammation on CD93 levels in murine models. Methods: We established an ovalbumin (OVA)-induced acute asthma murine model (OVA model) and a lipopolysaccharide (LPS)-induced airway inflammation murine model (LPS model). Dexamethasone was administered by gavage to attenuate the airway inflammation. Results: The OVA model demonstrated typical allergic asthma features with increased airway hyper-responsiveness, inflammatory cell infiltration, increased Th2 cytokine levels, compared to the control group. CD93 levels were decreased in lung homogenates and, respiratory epithelial cells, whereas serum sCD93 levels were increased in the OVA model, as compared to the control group. Dexamethasone reversed these effects of OVA. In contrast, in the LPS model, CD93 levels were not affected in neither respiratory epithelial cells nor serum. Conclusions: Our findings demonstrate the potential of using sCD93 as a biomarker for allergic asthma.",
author = "Park, {Hye Jung} and Oh, {Eun Yi} and Park, {Yoon Hee} and Misuk Yang and Park, {Kyung Hee} and Jungwon Park and Lee, {Jae Hyun}",
year = "2018",
month = "7",
day = "4",
doi = "10.1080/1354750X.2018.1443510",
language = "English",
volume = "23",
pages = "446--452",
journal = "Biomarkers",
issn = "1354-750X",
publisher = "Informa Healthcare",
number = "5",

}

Potential of serum soluble CD93 as a biomarker for asthma in an ovalbumin-induced asthma murine model. / Park, Hye Jung; Oh, Eun Yi; Park, Yoon Hee; Yang, Misuk; Park, Kyung Hee; Park, Jungwon; Lee, Jae Hyun.

In: Biomarkers, Vol. 23, No. 5, 04.07.2018, p. 446-452.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Potential of serum soluble CD93 as a biomarker for asthma in an ovalbumin-induced asthma murine model

AU - Park, Hye Jung

AU - Oh, Eun Yi

AU - Park, Yoon Hee

AU - Yang, Misuk

AU - Park, Kyung Hee

AU - Park, Jungwon

AU - Lee, Jae Hyun

PY - 2018/7/4

Y1 - 2018/7/4

N2 - Background: CD93 is a membrane-associated glycoprotein, which can be released in a soluble form (sCD93) into the serum. CD93 has received renewed attention as a candidate biomarker of inflammation in various inflammatory and immune-mediated diseases, including asthma. Objective: We aimed to evaluate the effects of airway inflammation on CD93 levels in murine models. Methods: We established an ovalbumin (OVA)-induced acute asthma murine model (OVA model) and a lipopolysaccharide (LPS)-induced airway inflammation murine model (LPS model). Dexamethasone was administered by gavage to attenuate the airway inflammation. Results: The OVA model demonstrated typical allergic asthma features with increased airway hyper-responsiveness, inflammatory cell infiltration, increased Th2 cytokine levels, compared to the control group. CD93 levels were decreased in lung homogenates and, respiratory epithelial cells, whereas serum sCD93 levels were increased in the OVA model, as compared to the control group. Dexamethasone reversed these effects of OVA. In contrast, in the LPS model, CD93 levels were not affected in neither respiratory epithelial cells nor serum. Conclusions: Our findings demonstrate the potential of using sCD93 as a biomarker for allergic asthma.

AB - Background: CD93 is a membrane-associated glycoprotein, which can be released in a soluble form (sCD93) into the serum. CD93 has received renewed attention as a candidate biomarker of inflammation in various inflammatory and immune-mediated diseases, including asthma. Objective: We aimed to evaluate the effects of airway inflammation on CD93 levels in murine models. Methods: We established an ovalbumin (OVA)-induced acute asthma murine model (OVA model) and a lipopolysaccharide (LPS)-induced airway inflammation murine model (LPS model). Dexamethasone was administered by gavage to attenuate the airway inflammation. Results: The OVA model demonstrated typical allergic asthma features with increased airway hyper-responsiveness, inflammatory cell infiltration, increased Th2 cytokine levels, compared to the control group. CD93 levels were decreased in lung homogenates and, respiratory epithelial cells, whereas serum sCD93 levels were increased in the OVA model, as compared to the control group. Dexamethasone reversed these effects of OVA. In contrast, in the LPS model, CD93 levels were not affected in neither respiratory epithelial cells nor serum. Conclusions: Our findings demonstrate the potential of using sCD93 as a biomarker for allergic asthma.

UR - http://www.scopus.com/inward/record.url?scp=85045249659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045249659&partnerID=8YFLogxK

U2 - 10.1080/1354750X.2018.1443510

DO - 10.1080/1354750X.2018.1443510

M3 - Article

C2 - 29498549

AN - SCOPUS:85045249659

VL - 23

SP - 446

EP - 452

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

IS - 5

ER -